Maravai LifeSciences Holdings, Inc. (MRVI) Stock Analysis
Healthcare · Biotechnology · NasdaqGS
Maravai LifeSciences Holdings, Inc. (MRVI) posted $185.74M in revenue for fiscal 2025 (down 28.3% year over year), with a net loss of $130.77M, and has compounded revenue about -8.1%/yr over five years, per its SEC filings.
Data last refreshed August 2, 2026 from SEC filings · how we compute this
The analyst's take on Maravai LifeSciences Holdings, Inc.
Maravai LifeSciences Holdings, Inc. has grown revenue from $143.14M to $185.74M over the last 7 fiscal years, compounding about -8.1% a year. The most recent year was down 28.3%, so growth has cooled from its longer-run pace.
Net margin sits at -70.4%, down 14.5 points year over year on a 18.3% gross margin. It carries about $291.77M of total debt.
The one thing worth a second look in the filings is share count rising (dilution).
Synthesised from Maravai LifeSciences Holdings, Inc.'s SEC filings — descriptive, not advice. Ask the analyst your own question →
Maravai LifeSciences Holdings, Inc. revenue & earnings — last 7 fiscal years
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $143.14M | $284.10M | $799.24M | $883.00M | $288.94M | $259.19M | $185.74M |
| Gross profit | $76.29M | $204.45M | $658.68M | $714.04M | $140.20M | $108.31M | $33.99M |
| Net income | $-4.47M | $88.97M | $182.04M | $220.21M | $-119.03M | $-144.85M | $-130.77M |
| Net margin | -3.1% | 31.3% | 22.8% | 24.9% | -41.2% | -55.9% | -70.4% |
Source: Maravai LifeSciences Holdings, Inc. SEC filings (10-K).
Maravai LifeSciences Holdings, Inc.: 3 potential red flags in the filings
Patterns in the filed statements worth a second look — computed and cited, not AI guesswork, and not a signal to sell. The kind of thing that hides in a 10-K.
- Share count rising (dilution)Shares outstanding grew 10.4% over 3 years (131.7M → 145.3M) — existing holders' stakes are being diluted.
- Debt with negative operating cash flowCarries $297.2M of debt while last year's operating cash flow was negative ($-57.6M).
- Currently unprofitableThe latest fiscal year was a net loss (net margin -70.4%).
Explore 7 years of Maravai LifeSciences Holdings, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track MRVI in your portfolio →
Maravai LifeSciences Holdings, Inc. financial history by metric
About Maravai LifeSciences Holdings, Inc.
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS. The TRILINK segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, and oligonucleotide therapy, as well as molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, CleanCap capping technology-based oligonucleotide building blocks, and custom enzyme development and manufacturing; and research products for labeling and detecting proteins in cells and tissue samples. The CYGNUS segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, and antibody-based products to detect impurities during the production of biopharmaceutical products. It serves biopharmaceutical companies, and emerging biopharmaceutical and life sciences research companies; and academic research institutions and diagnostics companies. Maravai LifeSciences Holdings, Inc. was founded in 2014 and is headquartered in San Diego, California.
Maravai LifeSciences Holdings, Inc. — frequently asked questions
What is Maravai LifeSciences Holdings, Inc.'s revenue?
Maravai LifeSciences Holdings, Inc. (MRVI) reported revenue of $185.74M for fiscal year 2025, down 28.3% from the prior year, according to its SEC filings.
Is Maravai LifeSciences Holdings, Inc. profitable?
No — MRVI reported a net loss of $-130.77M in fiscal 2025.
What is MRVI's P/E ratio?
Maravai LifeSciences Holdings, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Maravai LifeSciences Holdings, Inc. growing?
MRVI's revenue grew at roughly -8.1% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does Maravai LifeSciences Holdings, Inc. have?
As of fiscal year 2025, MRVI carried roughly $291.77M in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is Maravai LifeSciences Holdings, Inc.'s gross margin?
MRVI's gross margin was 18.3% in fiscal 2025 — gross profit of $33.99M on revenue of $185.74M.
What is Maravai LifeSciences Holdings, Inc.'s market cap?
Maravai LifeSciences Holdings, Inc. (MRVI) has a market capitalization of about $1.89B, based on the latest data in our nightly-refreshed cache.
When does Maravai LifeSciences Holdings, Inc.'s fiscal year end?
MRVI's fiscal year ends in December. Its most recent annual filing covers the fiscal year ending 2025-12-31.
Where does this data come from?
All figures are computed from Maravai LifeSciences Holdings, Inc.'s official SEC filings (10-K and 10-Q), covering 7 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.